Neovare™ is dedicated to providing patients and healthcare professionals with reliable, high quality and affordable hereditary cancer testing solutions. This is backed by siParadigm’s proven know-how and 17 years of clinical oncology expertise through service, integrity and innovation.
Hereditary Cancer occurs when more than one incident of cancer in a family is passed down from generation to generation due to inherited genetic mutations. An inherited germ-line mutation is present in the maternal egg “ova” or paternal sperms that form the embryos. Since all body cells are formed by multiplication of the forming fused egg and sperm, a germ-line mutation is typically resent in all body cells and so passes on through generations. On the other hand, an acquired (somatic) mutation does not come from a parent but rather happen due to environmental or lifestyle-related risk actors. These mutations do not typically pass from generation to generation.
The NEOVARE™ Hereditary Cancer Test is easy and simple blood or saliva test that assesses the risk of developing cancer due to hereditary gene mutations and could be covered by your insurance if you meet the criteria of the National Comprehensive Cancer Network (National medical society guidelines).
Top-quality clinical testing is our priority and we use the latest technologies coupled with the most convenient billing method for you. We offer two tests to effectively asses your risk of developing hereditary cancer:
NEOVARE™ DIAGNOSTIC – This test is for patients who have a strong personal or family history of being a carrier of a hereditary cancer mutation. These patients meet the national medical society guidelines and in most cases are covered by their insurance provider. Since these patients are at high risk, we combine two different technologies (NGS and Microarray) for a comprehensive diagnostic panel.
NEOVARE™ SCREEN - This test is for patients who do not meet the national medical society guideline and therefore are not covered by insurance. This, however, does not mean they have zero risk of developing hereditary cancer. It only means that they are not at a higher risk than the average population. Since the national medical society guidelines don't cover all types of hereditary cancers, we offer our patients this test using Microarray Technology. The test is considered a screening test as it utilizes this technology to asses the 24,000 most common hereditary cancer mutations.
If you need to know more about hereditary cancer testing (before or after having the test), you can schedule an appointment with one of our board-certified genetic counselors at no cost.
For further information, please contact Dr. Safaa Hmady, MD - Medical Scientific Liaison - siParadigm Middle East